CHMFL-ABL-121

• UNSPSC Description:

  CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively[1].

• Target Antigen:

  Apoptosis; Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/chmfl-abl-121.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NC1=CC(C(F)(F)F)=C(CN2CCN(C)CC2)C=C1)CCSC3=CC(NN=C4/C=C/C5=CC=CC=N5)=C4C=C3

• Molecular Weight:

  580.67

• References & Citations:

  [1]Liu X, et al. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Eur J Med Chem. 2018 Dec 5;160:61-81.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2270879-07-5